Odevixibat

Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis[1].

Product Specifications

CAS Number

501692-44-0

Product Name Alternative

A4250

UNSPSC

12352005

Target

Apical Sodium-Dependent Bile Acid Transporter

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/odevixibat.html

Purity

99.92

Solubility

DMSO : 166.67 mg/mL (ultrasonic)

Smiles

CC[C@H](NC([C@H](NC(COC1=C(SC)C=C(C2=C1)N(C3=CC=CC=C3)CC(CCCC)(CCCC)NS2(=O)=O)=O)C4=CC=C(O)C=C4)=O)C(O)=O

Molecular Formula

C37H48N4O8S2

Molecular Weight

740.93

References & Citations

[1]Baghdasaryan A, et al. Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis.J Hepatol. 2016 Mar;64 (3) :674-81.